InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
0
T+90 hit rate
40%
T+90 mean return
-8.0%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Ling Karen, Director. Officer active across 4 companies, notably TherapeuticsMD, Inc.. Cumulatively, 17 disclosures have been published. Breakdown: 2 buys · 0 sell. Total volume traded: €82k. History available since 17 August 2021. The latest transaction was disclosed on 26 May 2026 (Attribution). Regulator: SEC (Form 4). The full history is openly available.
Declarations17 total
15,842 shares@ US$15.780.0037% mcap100.0% of flowCommon Shares, No Par ValueSEC:0001860742-26-000078:0
4,000 shares@ US$17.74221.9% of flowCommon Shares, No Par ValueSEC:0001860742-26-000020:0
Canonical exit: 20 May 2026 (T+90)
1,358 shares0Common StockSEC:0001388658-25-000129:0
20,338 shares0Common Shares, No Par ValueSEC:0001127602-25-015803:0
14,696 shares0Common Shares, No Par ValueSEC:0001127602-24-021757:0
1,841 shares0Common StockSEC:0001388658-24-000122:0
2,642 shares0Common Shares, No Par ValueSEC:0001127602-24-009005:0
23,122 shares0Ordinary SharesSEC:0001104659-23-119109:0
1,396 shares0Common StockSEC:0001388658-23-000128:0
3,154 shares@ US$1.28100.0% of flowOrdinary SharesSEC:0001104659-23-076469:0
1,164 shares0Common StockSEC:0001388658-23-000054:0
26,277 shares0Ordinary SharesSEC:0001104659-23-001542:0
1,984 sharesCommon StockSEC:0001209191-22-046965:0
653 shares0Common StockSEC:0001388658-22-000072:0
4,320 shares0Common StockSEC:0001388658-21-000147:0
33,445 shares@ US$0.750.093% mcap50.0% of flowCommon StockSEC:0001387131-21-008750:0
Canonical exit: 15 Nov 2021 (T+90)
96,864 sharesCommon StockSEC:0001387131-21-008433:0
17 of 17 declarations
About Ling Karen
Ling Karen serves as a Director at TherapeuticsMD, Inc. and iRhythm Technologies, Inc. She participates in the governance of these companies and strategic decision-making. Her expertise is valuable in guiding direction and ensuring performance.
